Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects
OA Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Com...
Saved in:
| Published in | Antimicrobial Agents and Chemotherapy Vol. 58; no. 3; pp. 1615 - 1621 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.03.2014
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0066-4804 1098-6596 1098-6596 |
| DOI | 10.1128/AAC.01786-13 |
Cover
| Abstract | OA
Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavorable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and nonobese healthy subjects. A single-dose, randomized, two-sequence crossover study was conducted in 12 obese and 12 nonobese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening washout period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a noncompartmental approach. The median (range) body mass indexes (BMIs) for obese subjects were 33.8 kg/m(2) (30.8 to 43.2) and 22.2 (18.8 to 24.2) for nonobese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and nonobese subjects for both 75-mg and 150-mg doses. Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects, there was no significant difference in the exposure of oseltamivir carboxylate between the obese and nonobese groups. Standard dosing is appropriate for obese subjects. (The study was registered at ClinicalTrials.gov under registration no. NCT 01049763.). Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavorable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and nonobese healthy subjects. A single-dose, randomized, two-sequence crossover study was conducted in 12 obese and 12 nonobese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening washout period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a noncompartmental approach. The median (range) body mass indexes (BMIs) for obese subjects were 33.8 kg/m 2 (30.8 to 43.2) and 22.2 (18.8 to 24.2) for nonobese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and nonobese subjects for both 75-mg and 150-mg doses. Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects, there was no significant difference in the exposure of oseltamivir carboxylate between the obese and nonobese groups. Standard dosing is appropriate for obese subjects. (The study was registered at ClinicalTrials.gov under registration no. NCT 01049763.) OA Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavorable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and nonobese healthy subjects. A single-dose, randomized, two-sequence crossover study was conducted in 12 obese and 12 nonobese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening washout period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a noncompartmental approach. The median (range) body mass indexes (BMIs) for obese subjects were 33.8 kg/m2 (30.8 to 43.2) and 22.2 (18.8 to 24.2) for nonobese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and nonobese subjects for both 75-mg and 150-mg doses. Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects, there was no significant difference in the exposure of oseltamivir carboxylate between the obese and nonobese groups. Standard dosing is appropriate for obese subjects. (The study was registered at ClinicalTrials.gov under registration no. NCT 01049763.) Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavorable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and nonobese healthy subjects. A single-dose, randomized, two-sequence crossover study was conducted in 12 obese and 12 nonobese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening washout period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a noncompartmental approach. The median (range) body mass indexes (BMIs) for obese subjects were 33.8 kg/m(2) (30.8 to 43.2) and 22.2 (18.8 to 24.2) for nonobese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and nonobese subjects for both 75-mg and 150-mg doses. Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects, there was no significant difference in the exposure of oseltamivir carboxylate between the obese and nonobese groups. Standard dosing is appropriate for obese subjects. (The study was registered at ClinicalTrials.gov under registration no. NCT 01049763.).Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was identified as a risk factor for severe disease and unfavorable outcomes. The aim of this study was to investigate the pharmacokinetic properties of oseltamivir and its active metabolite, oseltamivir carboxylate, in obese and nonobese healthy subjects. A single-dose, randomized, two-sequence crossover study was conducted in 12 obese and 12 nonobese healthy Thai volunteers. Each volunteer was given 75 mg and 150 mg oseltamivir orally with an intervening washout period of more than 3 days. The pharmacokinetic properties of oseltamivir and oseltamivir carboxylate were evaluated using a noncompartmental approach. The median (range) body mass indexes (BMIs) for obese subjects were 33.8 kg/m(2) (30.8 to 43.2) and 22.2 (18.8 to 24.2) for nonobese subjects. The pharmacokinetic parameters of oseltamivir carboxylate, the active metabolite of oseltamivir, were not significantly different between obese and nonobese subjects for both 75-mg and 150-mg doses. Both doses were well tolerated. Despite the lower dose per kilogram body weight in obese subjects, there was no significant difference in the exposure of oseltamivir carboxylate between the obese and nonobese groups. Standard dosing is appropriate for obese subjects. (The study was registered at ClinicalTrials.gov under registration no. NCT 01049763.). |
| Author | Sasithon Pukrittayakamee Saranath Lawpoolsri Nicholas J. White Walter Robert John Taylor Nicholas P. J. Day Podjanee Jittamala Prakaykaew Charunwattana Warunee Hanpithakpong Joel Tarning Salwaluk Panapipat Niklas Lindegardh |
| Author_xml | – sequence: 1 givenname: Podjanee surname: Jittamala fullname: Jittamala, Podjanee organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 2 givenname: Sasithon surname: Pukrittayakamee fullname: Pukrittayakamee, Sasithon organization: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 3 givenname: Joel surname: Tarning fullname: Tarning, Joel organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom – sequence: 4 givenname: Niklas surname: Lindegardh fullname: Lindegardh, Niklas organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom – sequence: 5 givenname: Warunee surname: Hanpithakpong fullname: Hanpithakpong, Warunee organization: Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom – sequence: 6 givenname: Walter Robert John surname: Taylor fullname: Taylor, Walter Robert John organization: Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom – sequence: 7 givenname: Saranath surname: Lawpoolsri fullname: Lawpoolsri, Saranath organization: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 8 givenname: Prakaykaew surname: Charunwattana fullname: Charunwattana, Prakaykaew organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand – sequence: 9 givenname: Salwaluk surname: Panapipat fullname: Panapipat, Salwaluk organization: Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom – sequence: 10 givenname: Nicholas J. surname: White fullname: White, Nicholas J. organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom – sequence: 11 givenname: Nicholas P. J. surname: Day fullname: Day, Nicholas P. J. organization: Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28269052$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24366750$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkc1v1DAQxS3Uim4LN84oHJBAaortxE5yQVqtgCJVLBLlbE3sSeMlsYudFO1_j9vd8iVV4mSN_Js38-YdkwPnHRLyjNEzxnj9ZrlcnVFW1TJnxSOyYLSpcykaeUAWlEqZlzUtj8hxjBuaatHQx-SIl4WUlaALoj73EEbQ_pt1OFkdM99l6wDDsM2WZrTOxgkDmmwdcZhgtDc2ZNZl5wjD1G-zdYsRM3Am--Sdvysue7DZl7ndoJ7iE3LYwRDx6f49IV_fv7tcnecX6w8fV8uLHAStphxRFLzkDKA0smsbNBTbUjQV7Yxo064AAjhjrOUGwYCUHWrGu1JyrdHUxQl5u9O9ntsRjUY3JRPqOtgRwlZ5sOrvH2d7deVvVNGIdLsqCbzaCwT_fcY4qdFGjcMADv0cFRNUFKUUov4flBVV2dQ0oa93KMSRq42fg0tXUIyq2-xUyk7dZadYkdjnf1r4tft9WAl4uQcgahi6AE7b-JuruWyo4InjO04HH2PATmk7wWT9rXM7PDT99J-me90H8Bc7vLdX_Q8bUCWHCkArUatCMclE8RM3584P |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1002_jcph_2326 crossref_primary_10_3390_pharmaceutics16020234 crossref_primary_10_1080_17425255_2018_1440287 crossref_primary_10_3389_fimmu_2019_01071 crossref_primary_10_1093_jtm_taz020 crossref_primary_10_1080_14656566_2024_2376660 crossref_primary_10_1055_a_2369_8680 crossref_primary_10_1007_s40266_024_01169_y crossref_primary_10_1111_bcp_12892 crossref_primary_10_1080_17425255_2022_2132931 crossref_primary_10_1002_phar_4621 crossref_primary_10_1080_17512433_2017_1255550 crossref_primary_10_1111_obr_12320 crossref_primary_10_1002_btm2_10196 crossref_primary_10_1128_aac_01719_23 crossref_primary_10_1097_MJT_0000000000000401 crossref_primary_10_1128_mbio_00887_23 crossref_primary_10_1586_14787210_2015_1043890 |
| Cites_doi | 10.1056/NEJMp068177 10.1093/epirev/mxm012 10.1378/chest.10-1160 10.1128/AAC.45.10.2723-2732.2001 10.1503/cmaj.092127 10.2165/00003088-199937060-00003 10.1093/jac/dkq013 10.1016/j.jchromb.2007.09.018 10.1093/cid/ciq152 10.1086/656316 10.1177/0091270007299761 10.1093/jac/dkq158 10.1093/epirev/mxm007 10.1345/aph.1H174 10.1128/AAC.45.4.1162-1167.2001 10.1093/jac/dkq015 10.1128/AAC.00422-11 10.1093/jac/dkr257 10.1111/j.1365-2125.2005.02340.x 10.1093/jac/dki018 10.3949/ccjm.77a.10135 10.1002/jps.22627 10.1378/chest.09-2517 10.1016/S0166-3542(00)00123-6 10.1093/jac/dkq511 10.1016/j.ijantimicag.2009.12.023 10.1046/j.1365-2125.2002.01678.x 10.1056/NEJMra1000449 10.1177/0091270012440280 10.47102/annals-acadmedsg.V36N4p285 10.1128/AAC.00588-08 10.1038/ijo.2008.102 10.1046/j.1440-6047.11.s8.12.x 10.1001/jama.2009.1536 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS Copyright © 2014 Jittamala et al. Copyright © 2014 Jittamala et al. 2014 Jittamala et al. |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: Copyright © 2014 Jittamala et al. – notice: Copyright © 2014 Jittamala et al. 2014 Jittamala et al. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7T2 7T7 7U1 8FD C1K FR3 P64 5PM |
| DOI | 10.1128/AAC.01786-13 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Health and Safety Science Abstracts (Full archive) Industrial and Applied Microbiology Abstracts (Microbiology A) Risk Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Risk Abstracts Technology Research Database Health & Safety Science Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE CrossRef Risk Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 1621 |
| ExternalDocumentID | PMC3957867 01786-13 24366750 28269052 10_1128_AAC_01786_13 aac_58_3_1615 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Thailand Asia |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 093956 |
| GroupedDBID | --- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM - 0R 55 AAPBV ABFLS ADACO BXI HZ RHF ZA5 7X8 7T2 7T7 7U1 8FD C1K FR3 P64 5PM |
| ID | FETCH-LOGICAL-a507t-ee532421aa4d6fb9ed0eb45970fd5b667aa5a2111b2deada66fec12f462cced83 |
| ISSN | 0066-4804 1098-6596 |
| IngestDate | Thu Aug 21 14:02:42 EDT 2025 Fri Sep 05 08:54:50 EDT 2025 Thu Sep 04 23:34:41 EDT 2025 Tue Dec 28 13:58:53 EST 2021 Sat May 31 02:12:52 EDT 2025 Wed Apr 02 07:28:55 EDT 2025 Tue Jul 01 04:32:21 EDT 2025 Thu Apr 24 22:55:12 EDT 2025 Wed May 18 15:26:31 EDT 2016 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Human Obesity Neuraminidase inhibitor Enzyme Nutrition disorder Oral administration Enzyme inhibitor Glycosylases Oseltamivir Exo-α-sialidase Glycosidases Hydrolases Antiviral Pharmacokinetics Nutritional status |
| Language | English |
| License | CC BY 4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license. http://creativecommons.org/licenses/by/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-a507t-ee532421aa4d6fb9ed0eb45970fd5b667aa5a2111b2deada66fec12f462cced83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC3957867 |
| PMID | 24366750 |
| PQID | 1501374980 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_1501374980 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3957867 pascalfrancis_primary_28269052 asm2_journals_10_1128_AAC_01786_13 pubmed_primary_24366750 crossref_primary_10_1128_AAC_01786_13 proquest_miscellaneous_1505346558 highwire_asm_aac_58_3_1615 crossref_citationtrail_10_1128_AAC_01786_13 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2014-03-01 |
| PublicationDateYYYYMMDD | 2014-03-01 |
| PublicationDate_xml | – month: 03 year: 2014 text: 2014-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAbbrev | Antimicrob Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2014 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_26_2 e_1_3_2_27_2 WHO (e_1_3_2_2_2) 2006 e_1_3_2_29_2 Roche Laboratories Inc (e_1_3_2_35_2) 2010 e_1_3_2_41_2 e_1_3_2_40_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_21_2 e_1_3_2_42_2 Lye DCB (e_1_3_2_13_2) 2007; 36 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 CDC (e_1_3_2_4_2) 2011 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_36_2 e_1_3_2_14_2 Aekplakorn W (e_1_3_2_32_2) 2004; 87 NIH (e_1_3_2_28_2) 2009 WHO (e_1_3_2_3_2) 2009 |
| References_xml | – ident: e_1_3_2_26_2 doi: 10.1056/NEJMp068177 – ident: e_1_3_2_23_2 – ident: e_1_3_2_27_2 doi: 10.1093/epirev/mxm012 – volume-title: Division of AIDS table for grading the severity of adult and pediatric adverse events year: 2009 ident: e_1_3_2_28_2 – ident: e_1_3_2_15_2 doi: 10.1378/chest.10-1160 – ident: e_1_3_2_43_2 doi: 10.1128/AAC.45.10.2723-2732.2001 – ident: e_1_3_2_11_2 doi: 10.1503/cmaj.092127 – volume: 87 start-page: 685 year: 2004 ident: e_1_3_2_32_2 article-title: Prevalence and determinants of overweight and obesity in Thai adults: results of the second national health examination survey publication-title: J. Med. Assoc. Thai. – ident: e_1_3_2_7_2 doi: 10.2165/00003088-199937060-00003 – ident: e_1_3_2_9_2 doi: 10.1093/jac/dkq013 – ident: e_1_3_2_30_2 doi: 10.1016/j.jchromb.2007.09.018 – ident: e_1_3_2_17_2 doi: 10.1093/cid/ciq152 – ident: e_1_3_2_12_2 doi: 10.1086/656316 – ident: e_1_3_2_40_2 doi: 10.1177/0091270007299761 – ident: e_1_3_2_22_2 – volume-title: Tamiflu (oseltamivir phosphate) package insert year: 2010 ident: e_1_3_2_35_2 – volume-title: Pharmacological management of pandemic influenza A (H1N1) 2009 and other influenza viruses year: 2009 ident: e_1_3_2_3_2 – ident: e_1_3_2_5_2 doi: 10.1093/jac/dkq158 – ident: e_1_3_2_24_2 doi: 10.1093/epirev/mxm007 – ident: e_1_3_2_37_2 doi: 10.1345/aph.1H174 – ident: e_1_3_2_42_2 doi: 10.1128/AAC.45.4.1162-1167.2001 – ident: e_1_3_2_6_2 doi: 10.1093/jac/dkq015 – ident: e_1_3_2_20_2 doi: 10.1128/AAC.00422-11 – ident: e_1_3_2_21_2 doi: 10.1093/jac/dkr257 – ident: e_1_3_2_36_2 doi: 10.1111/j.1365-2125.2005.02340.x – ident: e_1_3_2_8_2 doi: 10.1093/jac/dki018 – ident: e_1_3_2_14_2 doi: 10.3949/ccjm.77a.10135 – ident: e_1_3_2_31_2 doi: 10.1002/jps.22627 – ident: e_1_3_2_16_2 doi: 10.1378/chest.09-2517 – ident: e_1_3_2_41_2 doi: 10.1016/S0166-3542(00)00123-6 – ident: e_1_3_2_18_2 doi: 10.1093/jac/dkq511 – ident: e_1_3_2_34_2 doi: 10.1016/j.ijantimicag.2009.12.023 – ident: e_1_3_2_38_2 doi: 10.1046/j.1365-2125.2002.01678.x – volume-title: Rapid advice guidelines on pharmacological management of human infected with avian influenza A (H5N1) virus year: 2006 ident: e_1_3_2_2_2 – volume-title: Antiviral agents for the treatment and chemoprophylaxis of influenza. Recommendations of advisory committee on immunization practice (ACIP) year: 2011 ident: e_1_3_2_4_2 – ident: e_1_3_2_10_2 doi: 10.1056/NEJMra1000449 – ident: e_1_3_2_39_2 doi: 10.1177/0091270012440280 – volume: 36 start-page: 285 year: 2007 ident: e_1_3_2_13_2 article-title: Review of human infections with avian influenza H5N1 and proposed local clinical management guideline publication-title: Ann. Acad. Med. Singapore doi: 10.47102/annals-acadmedsg.V36N4p285 – ident: e_1_3_2_29_2 doi: 10.1128/AAC.00588-08 – ident: e_1_3_2_25_2 doi: 10.1038/ijo.2008.102 – ident: e_1_3_2_33_2 doi: 10.1046/j.1440-6047.11.s8.12.x – ident: e_1_3_2_19_2 doi: 10.1001/jama.2009.1536 |
| SSID | ssj0006590 |
| Score | 2.2459495 |
| Snippet | OA
Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley... Oseltamivir is the most widely used anti-influenza drug. In the 2009 H1N1 pandemic, in which the influenza viruses were oseltamivir sensitive, obesity was... |
| SourceID | pubmedcentral proquest asm2 pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1615 |
| SubjectTerms | Administration, Oral Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents Antiviral Agents - administration & dosage Antiviral Agents - blood Antiviral Agents - pharmacokinetics Biological and medical sciences Body Mass Index Cross-Over Studies Dose-Response Relationship, Drug Female Humans Male Medical sciences Metabolic diseases Middle Aged Obesity Obesity - metabolism Oseltamivir Oseltamivir - administration & dosage Oseltamivir - analogs & derivatives Oseltamivir - blood Oseltamivir - pharmacokinetics Pharmacology Pharmacology. Drug treatments Thailand Young Adult |
| Title | Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects |
| URI | http://aac.asm.org/content/58/3/1615.abstract https://www.ncbi.nlm.nih.gov/pubmed/24366750 https://journals.asm.org/doi/10.1128/AAC.01786-13 https://www.proquest.com/docview/1501374980 https://www.proquest.com/docview/1505346558 https://pubmed.ncbi.nlm.nih.gov/PMC3957867 |
| Volume | 58 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbGEIgXBANGB0wGwV66lNSx0_SxmkDTpG1FdNLeLCd2ttA2nZYUqfyV_EncJc6PTtsEvERt4sZO78v5zr77jpCPYNJrEw-1owZCO1yxgaOigXI0zHVhzBkPh5gofHziH57xo3NxvrHxuxW1tMzDXvTr1ryS_5EqnAO5YpbsP0i2vimcgM8gXziChOH4VzIeW97pKZiKBd0yWH6n12o2W9WkuFiKs3uamVmu5snPBIPPberRqotFAcrdg5NFuii-TC5VgsoEV2eytuE6SvNknhSsTSjUiyIxDn-KjAM2i6tenR8v9A-VGtM9SnLoV81q3f9dZQmyFXTHy-k1XlypqZqbGl1HGGk7KVdrmi2TKZj4xeqBuQBAX7ZXKvq8CdVqJQeg1mrFox4nDd9UW0_7vsODsjBxz5SqGZlPfVHWv610twhaGPVaihgN2dtnCIZZD6PRQQ90UYAcjO1mIN-reYEWxj0fnCm3mSer2IAb02cd1KhUJEUgPYl9PyAP2QCsOQwT-Nbw18P4y6Qo-3xVKgYLPreHhBTVtn8wFVQ2Z-tmU0VljZG8KoOXOS6rsNzmJt2M9m2ZT5Nn5Kn1e-ioBPFzsmHSLfKorIS62iKPj22MxxbZs6he7dNJkxyY7dM9Om541lcviLwJf7qIaQl_2oY_bcGfJim18KcF_ClgmFbwpwh_WsH_JTn7-mVycOjYeiGOAq8md4wR6B70leLaj0HJaNeEHDxmN9YihH9TKaEYTO4h06BAle_HJuqzmPssiowOvFdkM12k5jWhAY9C7UWB0JxzsHhDV7OhiL2YcxYOhdshH1Aq0iqDTBa-NAskSFEWUpR9r0O6lcxkZBn3sfDL7I7Wn-rWVyXTzB3tdirxSxiDXINdh-yuAaK-EwuYP3QF65D3FUIkTCS4Owj6YLGEJxDIPsqHgXtvG-Eh42LQIdslqpoeLGA7ZLCGt7oBEtmvX0mTy4LQHmMFAn-wc9-TvSFPGp3ylmzm10vzDvyBPNwtXrE_G5gPaA |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+Orally+Administered+Oseltamivir+in+Healthy+Obese+and+Nonobese+Thai+Subjects&rft.jtitle=Antimicrobial+Agents+and+Chemotherapy&rft.au=Podjanee+Jittamala&rft.au=Sasithon+Pukrittayakamee&rft.au=Joel+Tarning&rft.au=Niklas+Lindegardh&rft.date=2014-03-01&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=58&rft.issue=3&rft.spage=1615&rft_id=info:doi/10.1128%2FAAC.01786-13&rft_id=info%3Apmid%2F24366750&rft.externalDBID=n%2Fa&rft.externalDocID=aac_58_3_1615 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |